Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Bristol-Myers Squibb |
---|---|
Information provided by: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT00327015 |
The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe and works better than taking either saxagliptin or metformin alone
Condition | Intervention | Phase |
---|---|---|
Diabetes |
Drug: Saxagliptin Drug: Metformin Drug: Placebo Drug: pioglitazone |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study |
Official Title: | A Multicenter, Randomized, Double-Blind Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control |
Enrollment: | 1306 |
Study Start Date: | May 2006 |
Study Completion Date: | December 2008 |
Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Saxagliptin and Metformin (A): Experimental
PLUS open-label pioglitazone (as needed as rescue medication)
|
Drug: Saxagliptin
Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)
Drug: Metformin
Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)
Drug: pioglitazone
Tablets, Oral, 15-45 mg, as needed (12 months LT)
|
Saxagliptin and Metformin (B): Experimental
PLUS open-label pioglitazone (as needed as rescue medication)
|
Drug: Saxagliptin
Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)
Drug: Metformin
Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)
Drug: pioglitazone
Tablets, Oral, 15-45 mg, as needed (12 months LT)
|
Saxagliptin and Placebo (C): Experimental
PLUS open-label pioglitazone (as needed as rescue medication)
|
Drug: Saxagliptin
Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)
Drug: Placebo
Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
Drug: pioglitazone
Tablets, Oral, 15-45 mg, as needed (12 months LT)
|
Metformin and Placebo (D): Active Comparator
PLUS open-label pioglitazone (as needed as rescue medication)
|
Drug: Metformin
Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)
Drug: Placebo
Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
Drug: pioglitazone
Tablets, Oral, 15-45 mg, as needed (12 months LT)
|
All subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period. Subjects who complete the short-term period will be eligible to enter the long term extension period. Also, subjects in the short-term period who have an elevated blood sugar that requires additional medication for blood sugar control will be eligible to enter the long-term treatment extension period where they will receive pioglitazone (rescue medication) added onto their blinded study medication
Ages Eligible for Study: | 18 Years to 77 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Bristol-Myers Squibb | Bristol-Myers Squibb |
Responsible Party: | Bristol-Myers Squibb ( Study Director ) |
Study ID Numbers: | CV181-039 |
Study First Received: | May 15, 2006 |
Last Updated: | March 19, 2009 |
ClinicalTrials.gov Identifier: | NCT00327015 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Hypoglycemic Agents Metabolic Diseases Pioglitazone Metformin Diabetes Mellitus, Type 2 |
Diabetes Mellitus Endocrine System Diseases Endocrinopathy Glucose Metabolism Disorders Metabolic Disorder |
Hypoglycemic Agents Metabolic Diseases Pioglitazone Physiological Effects of Drugs Metformin |
Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Pharmacologic Actions |